Friday, August 3, 2018

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.


from Reuters: Health News https://ift.tt/2MbSZZU

Related Posts:

  • LATEST HEALTH NEWSU.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices - sometimes by more than 1,000% - and stifle competition for generic dru… Read More
  • LATEST HEALTH NEWSCigarette maker Philip Morris International Inc has suspended a global social media marketing campaign in response to Reuters inquiries into the company’s use of young online personalities to sell its new "heated tobacco" dev… Read More
  • LATEST HEALTH NEWSTeva Pharmaceutical Industries' chief financial officer on Sunday reiterated that the company has done nothing wrong in the wake of a price-fixing lawsuit filed by 44 U.S. states. from Reuters: Health News https://reut.r… Read More
  • LATEST HEALTH NEWSChina has pledged to stem a flood of the synthetic opioid fentanyl onto America's streets, where it kills thousands of people a month, but U.S. security experts are skeptical about whether Beijing is willing, or even able, to… Read More
  • LATEST HEALTH NEWSVietnam has culled more than 1.2 million farmed pigs infected with African swine fever, the government said on Monday, as the virus continues to spread rapidly in the Southeast Asian country. from Reuters: Health News ht… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner